# Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/development-of-pd-1-and-pd-l1-inhibitors-as-a-form-of-cancer-immunotherapy-a/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jun Gong,Alex Chehrazi‐Raffle,Srikanth Reddi,Ravi Salgia |
| Citations | 1,325 |
| DOI | 10.1186/s40425-018-0316-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-018-0316-z |
| OpenAlex ID | https://openalex.org/W2794577178 |
| PMID | 29357948 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Ravi Salgia](https://scholariq.org/researchers/ravi-salgia/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.